| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
Phase 2a interim results example | Phase 2a | — | Subscribe to access the data. | Small Molecules | Nervous System | ||
Phase 2a interim results example | Phase 2a | — | Subscribe to access the data. | Small Molecules | Nervous System | ||
Phase 2a interim results example | Phase 2a | — | Subscribe to access the data. | Small Molecules | Nervous System |
Recent Updates
Recently added Catalysts
CervoMed Inc.$2.58
+0.06 (+2.38%)
D 27Pipeline Score Richly Valued Biotech · Clinical
Market Cap
35.46 M
EPS
-2.97
P/E Ratio
-1.29 $
Value Trade
127.99 K
SEC Financials
Q1 2026Dilution Risk
Revenue
-
R&D Expenses
5.14 M
Operating CF
-8.02 M
Total Assets
15.11 M
Total Liabilities
4.50 M
Equity
10.62 M
D/E Ratio
12,345
-10.83 %
Week
-14.18 %
1 Month
-6.84 %
3 Month
-8.05 %
6 Month
-91.34 %
5 Year
-100 %
All Time
Cash Data
Cash Position
12.92 M
Monthly Burn
2.67 M
Runway
2.4 mo
Burn Trend
SEC Filing
May 15, 2026
Overview
Volume
238.56 K
52 Week Range
3.51 - 13.13
% held by Insiders
40.06 %
% held by Institutions
13.6 %
Enterprise Value
14.60 M
Total Shares
9.26 M
Short %
14.16 %
Float Shares
5.84 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for CervoMed Inc.
175Total events
9Upcoming
19Tier-1 (high impact)
2013 – 2027Coverage
Upcoming catalysts 2
TBD
T2Trial Initiation
Subscribe to view catalyst details
TBD
T1Interim Analysis
Subscribe to view catalyst details
Event history 2
TBD
◆Poster PresentationPresentation
Subscribe to view catalyst details
TBD
◆Oral PresentationNeflamapimodPresentation
Subscribe to view catalyst details
Past FDA Catalysts & PDUFA Decisions
| Date | Drug | Catalyst | Stage | Outcome | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|---|
2026-07-14 | neflamapimod 80 mg BID | Phase 2 data readout | Phase 2 | — | – | – | – |
2026-07-14 | neflamapimod 80 mg BID | Phase 2 data readout | Phase 2 | — | – | – | – |
2026-07-14 | neflamapimod 80 mg BID | Phase 2 data readout | Phase 2 | — | – | – | – |
Drug Pipeline Intelligence
D27
Pipeline Score $2M
Pipeline ValueRichly Valued
Valuation Signal1
Drugs Scored0.1x
rNPV / MCap Top 30%
Micro Cap (rank 640 of 913)
Percentile RankCervoMed Inc. faces pipeline headwinds (27/100), with $323M risk-adjusted pipeline value, led by Neflamapimod in Moderate to Severe Acute Ischaemic Stroke (Phase 2), but cash runway is a concern.
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| neflamapimod Small molecule | Dementia With Lewy Bodies (DLB) | Phase 2 | NCT06815965 | 43% | $323M | COMPLETED | 25 | SLOW | D (24) | Mar 25, 2026 | MODERATE_RISK | HIGH Aug 1, 2026 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Neflamapimod Orphan | Dementia with Lewy Bodies (DLB) | Phase 2b | 2026-07-14 | 80 mg twice-daily dose of neflamapimod met its primary safety, tolerability, and pharmacokinetic objectives; 159-patient Phase 2b RewinD-LB trial; 16-week randomized, double-blind, placebo-controlled study followed by a 32-week neflamapimod-only extension Read More | CervoMed Announces New Clinical, Plasma Biomarker and Imaging Data at AAIC 2026 for Neflamapimod in the Treatment of Dementia with Lewy Bodies (DLB) Read More | |
Neflamapimod Orphan | Dementia with Lewy Bodies (DLB) | Phase 2b | 2026-07-14 | 80 mg twice-daily dose of neflamapimod met its primary safety, tolerability, and pharmacokinetic objectives; 159-patient Phase 2b RewinD-LB trial; 16-week randomized, double-blind, placebo-controlled study followed by a 32-week neflamapimod-only extension Read More | CervoMed Announces New Clinical, Plasma Biomarker and Imaging Data at AAIC 2026 for Neflamapimod in the Treatment of Dementia with Lewy Bodies (DLB) Read More | |
Neflamapimod Orphan | Dementia with Lewy Bodies (DLB) | Phase 2b | 2026-07-14 | 80 mg twice-daily dose of neflamapimod met its primary safety, tolerability, and pharmacokinetic objectives; 159-patient Phase 2b RewinD-LB trial; 16-week randomized, double-blind, placebo-controlled study followed by a 32-week neflamapimod-only extension Read More | CervoMed Announces New Clinical, Plasma Biomarker and Imaging Data at AAIC 2026 for Neflamapimod in the Treatment of Dementia with Lewy Bodies (DLB) Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in CRVO
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
CRVO Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
CRVO▼ -6.9%on this news
CervoMed Announces New Clinical, Plasma Biomarker and Imaging Data at AAIC 2026 for Neflamapimod in the Treatment of Dementia with Lewy Bodies (DLB)
CervoMed presented new data on neflamapimod at AAIC 2026, highlighting its potential in treating Dementia with Lewy Bodies (DLB). The analyses from the Phase 2b trial showed a durable treatment effect and supported the dosing strategy for an upcoming Phase 3 study. However, challenges in replicating earlier positive results were noted due to patient selection and drug concentration issues.
Read more →CRVO▲ +9.7%on this newsshared move
CervoMed Announces Completion of Enrollment in Phase 2 Study of Neflamapimod for Nonfluent Variant Primary Progressive Aphasia, a Type of Frontotemporal Dementia
CervoMed Inc. has completed enrollment in its Phase 2a study of neflamapimod for treating nonfluent variant primary progressive aphasia (nfvPPA), a type of frontotemporal dementia. The study aims to assess the drug's safety and efficacy, with interim biomarker data expected to be presented at the upcoming CTAD conference. This development highlights the urgency for effective treatments in a condition currently lacking approved therapies.
Read more →CRVOCervoMed Showcases Leadership in Advancing the Treatment and Care of Dementia with Lewy Bodies at the Alzheimer's Association International Conference (AAIC) 2026
CervoMed Inc. will present five studies on neflamapimod at the AAIC 2026, showcasing its potential in treating dementia with Lewy bodies (DLB). The findings highlight the drug's impact on disease progression and biomarkers. Despite the lack of approved treatments for DLB, the data from clinical trials suggest neflamapimod could significantly benefit patients.
Read more →CRVO▼ -9.9%on this news· ran to -21% by day 1
CervoMed Announces Closing of $10 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules
CervoMed Inc. has completed a registered direct offering, raising $10 million by selling 2.5 million shares at $4.00 each. The funds are intended for working capital and corporate purposes. The company has also aligned with the FDA on a potential registration path for its lead drug candidate, neflamapimod, in treating dementia with Lewy bodies.
Read more →CRVO▼ -43.2%on this news· ran to -56% by day 3shared move
CervoMed Announces $10 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules
CervoMed Inc. has announced a registered direct offering of 2.5 million shares of common stock at $4.00 per share, aiming to raise $10 million. The offering is expected to close around June 22, 2026, pending customary conditions. Proceeds will be used for working capital and corporate purposes, supporting the company's ongoing clinical trials and development efforts.
Read more →CRVO▲ +11.3%on this newsshared move
CervoMed Secures New U.S. Patent Protecting Use of Neflamapimod in Pure Dementia with Lewy Body Patients into 2042
CervoMed Inc. has received a notice of allowance for a new patent protecting the use of neflamapimod in treating dementia with Lewy bodies without significant Alzheimer’s pathology. This patent is expected to provide protection until 2042. Currently, there are no approved treatments for this condition, and the company is working towards initiating a Phase 3 trial, contingent on partnerships and funding.
Read more →CRVOCervoMed to Participate in the H.C. Wainwright 7th Annual Neuro Perspectives Expert Summit
CervoMed Inc. will participate in the H.C. Wainwright 7th Annual Neuro Perspectives Expert Summit on June 15, 2026. The company will engage in a fireside chat and one-on-one investor meetings. CervoMed is focused on developing treatments for age-related brain disorders, including its lead candidate, neflamapimod, which has shown promise in clinical trials.
Read more →CRVO▼ -22.1%on this newsshared move
CervoMed Announces Private Placement Financing and Plan to Focus on Strategic Partnering to Advance Neflamapimod into Phase 3 for Dementia with Lewy Bodies
CervoMed Inc. announced a $10.5 million private placement to extend its cash runway into 2027 and focus on establishing a partnership to advance neflamapimod into Phase 3 for dementia with Lewy bodies (DLB). The company has achieved significant progress in clinical trials and is aligned with regulatory bodies on a potential registration path for neflamapimod. Upcoming milestones include data from ongoing trials in related neurological disorders.
Read more →CRVO▼ -11.6%on this news
CervoMed Reports First Quarter 2026 Financial Results and Provides Corporate Updates
CervoMed Reports First Quarter 2026 Financial Results and Provides Corporate Updates
Read more →CRVOCervoMed Announces New Data at the 2026 AAN Annual Meeting that Demonstrated Neflamapimod Increased Basal Forebrain Volume and Functional Connectivity in Dementia with Lewy Bodies
CervoMed Announces New Data at the 2026 AAN Annual Meeting that Demonstrated Neflamapimod Increased Basal Forebrain Volume and Functional Connectivity in Dementia with Lewy Bodies
Read more →CRVOCervoMed to Provide Neflamapimod Clinical Program Update and Participate in a Panel on Biomarkers at 2026 Lewy Body Dementia Association Annual Meeting
CervoMed to Provide Neflamapimod Clinical Program Update and Participate in a Panel on Biomarkers at 2026 Lewy Body Dementia Association Annual Meeting
Read more →CRVOCervoMed Announces New Data at the AD/PD 2026 Scientific Conference that Reinforce Neflamapimod's Positive Effects in Dementia with Lewy Bodies (DLB) in Patients without Alzheimer's Disease Co-Pathology
CervoMed Announces New Data at the AD/PD 2026 Scientific Conference that Reinforce Neflamapimod's Positive Effects in Dementia with Lewy Bodies (DLB) in Patients without Alzheimer's Disease Co-Pathology
Read more →CRVO▲ +5.1%on this newsshared move
CervoMed Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Updates
CervoMed Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Updates
Read more →CRVOCervoMed Announces Presentations at Upcoming AD/PD™ 2026 Scientific Conference
CervoMed Inc. announced that its drug candidate neflamapimod will be featured at the AD/PD 2026 conference in Copenhagen. The presentations will focus on the drug's efficacy in dementia with Lewy bodies (DLB) and its planned Phase 3 trial. CervoMed aims to enrich the patient population for the trial by excluding those with Alzheimer’s disease co-pathology. The company is also sponsoring a symposium on advancements in DLB research.
Read more →CRVOCervoMed to Participate in Upcoming Investor Conferences
CervoMed Inc. (NASDAQ: CRVO) announced its participation in two investor conferences in March 2026. The company will hold 1x1 meetings at the Leerink Global Healthcare Conference and a fireside chat at the ROTH Conference. CervoMed is developing neflamapimod for age-related brain disorders and plans to initiate a Phase 3 trial later this year.
Read more →CRVOCervoMed Announces Selection of Formulation and Dosing Regimen for Planned Phase 3 Trial in Patients with Dementia with Lewy Bodies
CervoMed has announced the selection of a 50mg TID dosing regimen for its planned Phase 3 trial of neflamapimod in patients with dementia with Lewy bodies. This decision follows a successful Phase 1 study that demonstrated a favorable pharmacokinetic profile for a new stable crystal form of the drug. The company aims to align plasma drug concentrations with those observed in prior successful trials.
Read more →CRVO▲ +8.6%on this news
CervoMed’s neflamapimod elected for inclusion in UK EXPERTS-ALS platform designed to prioritize promising treatments for Amyotrophic Lateral Sclerosis
CervoMed's neflamapimod has been selected for the UK EXPERTS-ALS platform, which aims to expedite the evaluation of treatments for amyotrophic lateral sclerosis (ALS). The trial will assess the drug's impact on neurofilament light chain (NfL) levels in ALS patients, with the first participant expected to be dosed by the end of 2026. This endorsement is based on neflamapimod's mechanism of action and previous clinical efficacy in related conditions.
Read more →CRVO▲ +9.4%on this news
CervoMed Announces Late-Breaking Data at the 18th CTAD Conference Demonstrating Neflamapimod Significantly Slows Clinical Progression in Dementia with Lewy Bodies
CervoMed Announces Late-Breaking Data at the 18th CTAD Conference Demonstrating Neflamapimod Significantly Slows Clinical Progression in Dementia with Lewy Bodies
Read more →CRVO▼ -10.8%on this newsshared move
CervoMed Presents New Plasma Biomarker Data That Indicates Neflamapimod Broadly Improves Neuroinflammation and Neurodegeneration in Dementia with Lewy Bodies (DLB)
CervoMed presented promising data from its Phase 2b study of neflamapimod at the CTAD Conference. The treatment significantly reduced plasma GFAP levels and improved the A42/40 ratio in patients with Dementia with Lewy Bodies (DLB). These findings suggest neflamapimod may effectively target neuroinflammation and neurodegeneration, supporting its potential for future Phase 3 trials.
Read more →CRVOCervoMed to Share New Data on Neflamapimod as a Treatment for Dementia with Lewy Bodies at the 18th Clinical Trials on Alzheimer's Disease (CTAD) Conference
CervoMed Inc. announced that neflamapimod will be featured in two presentations at the upcoming CTAD Conference. The late-breaking oral session will present full results from the Phase 2b RewinD-LB trial, while a poster session will highlight findings on neurodegeneration biomarkers. The drug aims to address the unmet need in treating Dementia with Lewy Bodies.
Read more →CRVOCervoMed Reports Third Quarter 2025 Financial Results and Provides Corporate Updates
CervoMed reported its Q3 2025 financial results, highlighting alignment with the FDA on the Phase 3 trial design for neflamapimod in dementia with Lewy bodies (DLB). The Phase 2b RewinD-LB trial demonstrated significant clinical benefits and biomarker improvements. The company anticipates initiating a global pivotal trial in late 2026 and has ongoing studies in related dementia conditions.
Read more →CRVOCervoMed Announces Alignment with FDA on Registration Path for Neflamapimod in Dementia with Lewy Bodies
CervoMed has received FDA alignment on its Phase 3 trial design for neflamapimod, aimed at treating dementia with Lewy bodies. The trial will include approximately 300 patients and is set to begin in the second half of 2026. This marks a significant milestone for CervoMed, as there are currently no approved therapies for this condition in the U.S. or EU.
Read more →CRVOCervoMed Strengthens Board with Appointment of Life Sciences Business Strategy Leader David Quigley
CervoMed Inc. has appointed David Quigley to its Board of Directors, enhancing its strategic capabilities as the company prepares for a Phase 3 trial for neflamapimod in dementia with Lewy bodies (DLB). Quigley's extensive experience in life sciences and private equity is expected to support CervoMed's commercialization efforts. The company anticipates FDA feedback on its trial design in late 2025.
Read more →CRVO▲ +6.1%on this news
CervoMed to Present at the Emerging Growth Conference
CervoMed Inc. (NASDAQ: CRVO) will present at the Emerging Growth Conference on October 22, 2025. Matthew Winton, Ph.D., will lead the corporate presentation, discussing the company's focus on age-related neurologic disorders and their investigational drug, neflamapimod. This drug aims to address synaptic dysfunction linked to neurodegenerative diseases, following a completed Phase 2b trial.
Read more →CRVOCervoMed Announces New Data from Phase 2b Trial Demonstrating Neflamapimod's Potential as a Treatment for Dementia with Lewy Bodies
CervoMed has announced promising results from its Phase 2b trial of neflamapimod for dementia with Lewy bodies, showing significant improvements in clinical outcomes and biomarker reductions. The trial results suggest that neflamapimod may be effective for patients without Alzheimer's disease co-pathology. The company is awaiting FDA feedback on the Phase 3 trial design, expected later this quarter.
Read more →CRVOCervoMed Appoints Matthew Winton, Ph.D., as Chief Commercial and Business Officer
CervoMed Inc. has appointed Matthew Winton, Ph.D., as Chief Commercial and Business Officer. Dr. Winton brings nearly two decades of experience in biotechnology and will play a crucial role as the company progresses into late-stage Phase 3 development of neflamapimod, a treatment for dementia with Lewy bodies. His expertise is expected to enhance CervoMed's strategic growth and commercialization efforts.
Read more →CRVOCervoMed to Participate in the 4th Annual ROTH Healthcare Opportunities Conference
CervoMed Inc. will participate in the 4th Annual ROTH Healthcare Opportunities Conference on October 9, 2025. The company will engage in a panel discussion titled 'Small Firms Tackling Blockbuster Indications' and hold one-on-one meetings. CervoMed is focused on developing neflamapimod, a treatment for age-related neurologic disorders, which has shown potential in recent trials.
Read more →CRVOCervoMed Highlights Neflamapimod's Potential Benefits in Session on Dementia with Lewy Bodies at the 150th Annual American Neurology Association Conference
CervoMed Inc. presented the potential benefits of neflamapimod for treating Dementia with Lewy Bodies at the 150th Annual American Neurological Association conference. The Phase 2b trial demonstrated a 74% reduction in the risk of clinically significant worsening. The company is preparing to begin a Phase 3 trial and expects to align with the FDA on its design by late 2025.
Read more →CRVOCervoMed Reports Second Quarter 2025 Financial Results and Provides Corporate Updates
CervoMed Reports Second Quarter 2025 Financial Results and Provides Corporate Updates
Read more →CRVO▲ +7.7%on this news
CervoMed to Participate in the Canaccord Genuity 45th Annual Growth Conference
CervoMed Inc. (NASDAQ: CRVO) will participate in the Canaccord Genuity 45th Annual Growth Conference from August 12 to 14, 2025, in Boston, MA. The company aims to enhance visibility by hosting a fireside chat and conducting one-on-one meetings with investors. CervoMed is developing neflamapimod, an investigational treatment for age-related neurologic disorders, which is currently undergoing evaluation in a Phase 2b trial for patients with dementia with Lewy bodies (DLB). The webcast of the chat will be available on their website for interested stakeholders.
Read more →CRVOCervoMed Announces 32-Week Data from RewinD-LB Trial Extension Phase Showing Neflamapimod's Sustained Effect on Slowing Clinical Progression in Patients with Dementia with Lewy Bodies and Associated Reduction in a Key Plasma Biomarker of Neurodegeneration
CervoMed Announces 32-Week Data from RewinD-LB Trial Extension Phase Showing Neflamapimod's Sustained Effect on Slowing Clinical Progression in Patients with Dementia with Lewy Bodies and Associated Reduction in a Key Plasma Biomarker of Neurodegeneration
Read more →CRVOCervoMed to Present New Data from Phase 2b RewinD-LB Study at AAIC 2025 and Host Conference Call on July 28, 2025
CervoMed to Present New Data from Phase 2b RewinD-LB Study at AAIC 2025 and Host Conference Call on July 28, 2025
Read more →CRVO▲ +7.4%on this news· ran to +22% by day 3
CervoMed Announces Late-Breaking Presentations at Alzheimer's Association International Congress 2025
CervoMed Announces Late-Breaking Presentations at Alzheimer's Association International Congress 2025
Read more →CRVOCervoMed Announces New Hire to Support Neflamapimod Development and Commercialization
CervoMed Announces New Hire to Support Neflamapimod Development and Commercialization
Read more →CRVO▲ +7.2%on this news
CervoMed Reports First Quarter 2025 Financial Results and Provides Corporate Updates
CervoMed Reports First Quarter 2025 Financial Results and Provides Corporate Updates
Read more →CRVO▼ -5%on this newsshared move
CervoMed to Participate in H.C. Wainwright 3rd Annual BioConnect Investor Conference
CervoMed to Participate in H.C. Wainwright 3rd Annual BioConnect Investor Conference
Read more →CRVO▼ -11.9%on this news· ran to -25% by day 1
Investigators to Present Clinical Trial Results Showing Neflamapimod Slows Clinical Progression in Dementia with Lewy Bodies in Oral Presentation at AD/PD 2025
Investigators to Present Clinical Trial Results Showing Neflamapimod Slows Clinical Progression in Dementia with Lewy Bodies in Oral Presentation at AD/PD 2025
Read more →CRVO▼ -17.4%on this news· ran to -28% by day 1
CervoMed Announces Oral Presentation at 19th International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurologic Disorders (AP/PD™)
CervoMed Inc. has announced an oral presentation at the 19th International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurologic Disorders, scheduled for April 1-5, 2025, in Vienna, Austria. The presentation will feature results from the Extension Phase of the RewinD-LB Phase 2b study concerning neflamapimod as a treatment for dementia with Lewy bodies. Key presenters include CervoMed's CEO and a prominent neurologist from Harvard Medical School, indicating a significant emphasis on the study’s findings.
Read more →CRVO▲ +40.5%on this news· ran to +80% by day 3
CervoMed Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Updates
CervoMed Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Updates
Read more →CRVOCervoMed Announces Positive Results from the Extension Phase of its Phase 2b Clinical Study of Neflamapimod in Patients with Dementia with Lewy Bodies
CervoMed Announces Positive Results from the Extension Phase of its Phase 2b Clinical Study of Neflamapimod in Patients with Dementia with Lewy Bodies
Read more →CRVOCervoMed Provides Update on Neflamapimod DLB Program as Part of Presentation at the 8th International Lewy Body Dementia Conference
CervoMed Provides Update on Neflamapimod DLB Program as Part of Presentation at the 8th International Lewy Body Dementia Conference
Read more →CRVOCervoMed to Present at the 8th International Lewy Body Dementia Conference
CervoMed Inc. (NASDAQ: CRVO) announced that it will present topline results from its Phase 2b RewinD-LB study at the 8th International Lewy Body Dementia Conference in Amsterdam on January 31, 2025. The presentation will focus on the efficacy and safety of neflamapimod in treating dementia with Lewy bodies. Previously disclosed initial results for the study were shared on December 10, 2024. The session will be led by John Alam, the company CEO and co-principal investigator of the study.
Read more →CRVOCervoMed Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CervoMed Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Read more →CRVO▼ -78.9%on this newsshared move
CervoMed Announces Topline Data from RewinD-LB Phase 2b Clinical Trial in Patients with Dementia with Lewy Bodies
CervoMed Announces Topline Data from RewinD-LB Phase 2b Clinical Trial in Patients with Dementia with Lewy Bodies
Read more →CRVO▲ +14.7%on this news· ran to +35% by day 1
CervoMed Announces Orphan Drug Designation Granted to Neflamapimod by U.S. Food and Drug Administration for the Treatment of Frontotemporal Dementia
CervoMed Announces Orphan Drug Designation Granted to Neflamapimod by U.S. Food and Drug Administration for the Treatment of Frontotemporal Dementia
Read more →CRVO▼ -5.2%on this news
CervoMed Announces Key Senior Leadership Appointments
CervoMed Inc. (NASDAQ: CRVO) announced key senior leadership appointments to drive the development of neflamapimod, targeting dementia with Lewy Bodies (DLB). Dr. Claudia Ordonez joins as Senior Vice President, Medical Science, bringing extensive drug development experience. Mark De Rosch is appointed as Senior Vice President in Regulatory Affairs, with over 30 years in the biotech industry. The company remains focused on achieving clinical milestones, with topline data from the RewinD-LB study expected in December 2024.
Read more →CRVOCervoMed Reports Third Quarter 2024 Financial Results and Provides Corporate Updates
CervoMed Reports Third Quarter 2024 Financial Results and Provides Corporate Updates
Read more →CRVOCervoMed Awarded the Prix Galien USA 2024 Prize for Best Startup
CervoMed Inc. has been awarded the Prix Galien USA 2024 prize in the Best Startup category, recognizing its innovative work in developing treatments for Dementia with Lewy bodies (DLB). The company aims to advance its investigational drug, neflamapimod, through the RewinD-LB Phase 2b clinical trial, with topline results expected in December 2024. This award reflects the company's potential to bring a breakthrough treatment to a condition affecting over 1.4 million patients in the U.S. and EU, for which no approved therapies currently exist.
Read more →CRVOCervoMed Announces Key Takeaways from Oral Presentations at the 17th Clinical Trials on Alzheimer's Disease Conference (CTAD)
CervoMed Announces Key Takeaways from Oral Presentations at the 17th Clinical Trials on Alzheimer's Disease Conference (CTAD)
Read more →CRVOCervoMed to Deliver Oral Presentation at the 8th International Lewy Body Dementia Conference
CervoMed to Deliver Oral Presentation at the 8th International Lewy Body Dementia Conference
Read more →CRVOCervoMed Announces Last Patient Last Visit in Phase 2b RewinD-LB Trial of Neflamapimod for the Treatment of Early-Stage Dementia with Lewy Bodies (DLB)
CervoMed Announces Last Patient Last Visit in Phase 2b RewinD-LB Trial of Neflamapimod for the Treatment of Early-Stage Dementia with Lewy Bodies (DLB)
Read more →CRVOCervoMed to Participate in 3rd Annual ROTH Healthcare Opportunities Conference
CervoMed Inc. (NASDAQ: CRVO) will participate in the 3rd Annual ROTH Healthcare Opportunities Conference on October 9, 2024, in New York, NY. CEO Dr. John Alam is set to engage in a panel discussion focusing on the challenges and opportunities faced by smaller companies in pursuing blockbuster drug indications. CervoMed is developing neflamapimod, a treatment currently in Phase 2b trials for early-stage dementia with Lewy bodies (DLB), which targets synaptic dysfunction associated with neurodegenerative diseases.
Read more →CRVO▲ +5.8%on this news
CervoMed to Deliver Late-Breaking Oral Presentations at the 17th Clinical Trials on Alzheimer's Disease Conference (CTAD)
CervoMed to Deliver Late-Breaking Oral Presentations at the 17th Clinical Trials on Alzheimer's Disease Conference (CTAD)
Read more →CRVOCervoMed Featured in Fortune for Advances in the Treatment of Dementia with Lewy Bodies
CervoMed Featured in Fortune for Advances in the Treatment of Dementia with Lewy Bodies
Read more →CRVO▲ +7.5%on this news· ran to +51% by day 3
CervoMed Reports Second Quarter 2024 Financial Results and Provides Corporate Updates
CervoMed Reports Second Quarter 2024 Financial Results and Provides Corporate Updates
Read more →CRVOCervoMed to Participate in The Canaccord Genuity 44th Annual Growth Conference
CervoMed Inc. (NASDAQ: CRVO) announced its participation in the Canaccord Genuity 44th Annual Growth Conference, where company management will engage in a fireside chat and one-on-one investor meetings. The event is set for August 13, 2024, in Boston, MA. CervoMed is focused on developing neflamapimod, a treatment for age-related neurologic disorders currently in a Phase 2b study targeting Dementia with Lewy Bodies (DLB). Interested investors can access the webcast through the CervoMed website.
Read more →CRVOCervoMed Announces Presentation at AAIC 2024 on Plasma Biomarker Data That Are Consistent with Neflamapimod Impacting the Underlying Disease Process in Patients with Dementia with Lewy bodies (DLB)
CervoMed Announces Presentation at AAIC 2024 on Plasma Biomarker Data That Are Consistent with Neflamapimod Impacting the Underlying Disease Process in Patients with Dementia with Lewy bodies (DLB)
Read more →CRVO▼ -6.7%on this news· ran to -23% by day 3
CervoMed to Participate in the Emerging Growth Conference
CervoMed Inc. will present virtually at the Emerging Growth Conference on July 18, 2024. The company focuses on developing treatments for age-related neurologic disorders, particularly through its investigational drug, neflamapimod. This small molecule aims to address synaptic dysfunction in neurodegenerative diseases, including dementia with Lewy bodies (DLB). Currently, neflamapimod is under investigation in a Phase 2b study.
Read more →CRVO▲ +5.6%on this news· ran to +31% by day 3
CervoMed to Host Virtual KOL Event on Neflamapimod for Dementia with Lewy Bodies on July 23, 2024
CervoMed to Host Virtual KOL Event on Neflamapimod for Dementia with Lewy Bodies on July 23, 2024
Read more →CRVOCervoMed Announces Addition to Russell 2000 and Russell 3000 Indexes
CervoMed Inc. (NASDAQ: CRVO) has announced its expected inclusion in the Russell 2000 and Russell 3000 Indexes, effective July 1, 2024. This addition reflects the company's growing market recognition as it progresses in developing neflamapimod, a potential treatment for age-related neurologic disorders. As CervoMed approaches the reporting of topline results from its Phase 2b RewinD-LB trial in December 2024, the CEO expressed optimism about increased visibility and awareness due to this inclusion. Membership in these indexes provides broader access to institutional investors.
Read more →CRVOCervoMed Announces Completion of Enrollment in Phase 2b RewinD-LB Clinical Trial of Neflamapimod for the Treatment of Patients with Dementia with Lewy Bodies
CervoMed Announces Completion of Enrollment in Phase 2b RewinD-LB Clinical Trial of Neflamapimod for the Treatment of Patients with Dementia with Lewy Bodies
Read more →CRVO▼ -18.1%on this news
CervoMed to Appoint William Elder as Chief Financial Officer
CervoMed to Appoint William Elder as Chief Financial Officer
Read more →CRVOCervoMed Reports First Quarter 2024 Financial Results and Provides Corporate Updates
CervoMed Reports First Quarter 2024 Financial Results and Provides Corporate Updates
Read more →CRVOCervoMed Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Updates
CervoMed reported its fourth quarter and full year 2023 financial results, highlighting key developments including a $149.4 million private placement and expected completion of enrollment in the RewinD-LB Phase 2b trial by Q2 2024. Positive results from the AscenD-LB Phase 2a trial were published, suggesting potential effectiveness of neflamapimod in treating dementia with Lewy bodies. The company appointed Joshua Boger, Ph.D., as the new Chair of the Board, reinforcing its leadership strategy. The garnered funds and promising trial outcomes position CervoMed for a robust future in the biopharmaceutical sector.
Read more →CRVO▲ +18.8%on this newsshared move
CervoMed Announces Up to $149.4 Million Private Placement Financing Joined by Leading Healthcare Investors
CervoMed Announces Up to $149.4 Million Private Placement Financing Joined by Leading Healthcare Investors
Read more →CRVOCervoMed Announces Presentation of Biomarker Data from the AscenD-LB Phase 2a Trial and Preclinical Data Supporting Potential of Neflamapimod in Tau-Mediated Disease at AD/PD 2024
CervoMed Announces Presentation of Biomarker Data from the AscenD-LB Phase 2a Trial and Preclinical Data Supporting Potential of Neflamapimod in Tau-Mediated Disease at AD/PD 2024
Read more →CRVO▼ -7.3%on this news· ran to -18% by day 3
CervoMed to Participate in the BIO CEO and Investor Conference
CervoMed Inc. (NASDAQ: CRVO) announced its participation in the upcoming BIO CEO and Investor Conference scheduled for February 26, 2024, in New York City. The company is focused on developing treatments for degenerative brain diseases, particularly through its investigational drug, neflamapimod. This medication is being evaluated for its potential to treat synaptic dysfunction in conditions like dementia with Lewy bodies. CervoMed's management will also engage in one-on-one investor meetings during the conference.
Read more →CRVO▲ +27.1%on this news· ran to +47% by day 3
CervoMed Publishes Positive Results from AscenD-LB Phase 2a Trial in Peer-Reviewed Journal that Supports the Therapeutic Potential of Neflamapimod in Dementia with Lewy Bodies
CervoMed Publishes Positive Results from AscenD-LB Phase 2a Trial in Peer-Reviewed Journal that Supports the Therapeutic Potential of Neflamapimod in Dementia with Lewy Bodies
Read more →CRVO▲ +8.6%on this news· ran to +67% by day 3shared move
CervoMed Announces Appointment of Industry Leader Joshua Boger, Ph.D., as Chair of the Board
CervoMed Inc. has appointed Joshua Boger, Ph.D., an experienced industry leader and founder of Vertex Pharmaceuticals, as Chair of the Board. This change comes as the company aims to complete patient enrollment for its RewinD-LB Phase 2b clinical trial for neflamapimod, a drug targeting dementia with Lewy bodies, by the first half of 2024. With topline data expected in the second half of 2024, CervoMed is optimistic about the potential impact of neflamapimod, which has shown promise in improving dementia symptoms in earlier studies. Dr. Boger brings extensive expertise in drug development to the company at a crucial time for its clinical programs.
Read more →CRVOCervoMed to Participate in the Emerging Growth Conference 67
CervoMed Inc. (NASDAQ: CRVO) will participate in the Emerging Growth Conference 67, providing a corporate update on February 7, 2024. The conference will allow CervoMed to present their innovations in treating degenerative brain diseases, including their investigational drug neflamapimod. This drug addresses synaptic dysfunction and is currently in Phase 2b trials for dementia with Lewy bodies. The presentation will be accessible via a live webcast and later available for replay.
Read more →CRVOCervoMed to Participate in the Emerging Growth Conference 66
CervoMed to Participate in the Emerging Growth Conference 66
Read more →CRVOCervoMed Reports Third Quarter 2023 Financial Results and Business Highlights
CervoMed Reports Third Quarter 2023 Financial Results and Business Highlights
Read more →CRVOCervoMed Reports Third Quarter 2023 Financial Results and Business Highlights Dosed first patient in Phase 2b RewinD-LB study evaluating neflamapimod in patients with dementia with Lewy bodies (DLB) Multiple peer-reviewed...
CervoMed Inc. reported its third-quarter financial results, highlighting the dosing of the first patient in the Phase 2b RewinD-LB study for dementia with Lewy bodies (DLB). The company completed a reverse merger and is now publicly traded on Nasdaq under the ticker CRVO. With a cash runway extending through 2024, CervoMed anticipates topline efficacy results from the study by the end of next year.
Read more →CRVO▼ -5.4%on this news· ran to -18% by day 3
CervoMed Announces Oral Presentation at CTAD 2023 Highlighting Learnings from Phase 2a Which Optimized the Design of the Phase 2b Clinical Study of Neflamapimod in Dementia with Lewy Bodies CervoMed Inc. (NASDAQ: CRVO), a clinical-stage company focused on developing treatments for degenerative diseases of the brain, announced an oral...
CervoMed Inc. announced an oral presentation at the CTAD 2023 conference regarding its Phase 2b study of neflamapimod for dementia with Lewy bodies. The study design incorporates key insights from the Phase 2a trial, aiming for over 95% statistical power to meet its primary endpoint. Initial results from the study are expected in the second half of 2024.
Read more →CRVO▼ -5.4%on this news· ran to -18% by day 3
CervoMed Announces Publications in Major Peer-Reviewed Journals That Inform on Potential of Neflamapimod as a Disease-Modifying Therapy for the Major Dementias
CervoMed Announces Publications in Major Peer-Reviewed Journals That Inform on Potential of Neflamapimod as a Disease-Modifying Therapy for the Major Dementias
Read more →CRVOCervoMed Announces Publications in Major Peer-Reviewed Journals That Inform on Potential of Neflamapimod as a Disease-Modifying Therapy for the Major Dementias CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for degenerative diseases of the brain, today announced the...
CervoMed Inc. has announced two significant publications supporting neflamapimod as a disease-modifying treatment for Dementia with Lewy Bodies and Alzheimer's Disease. The Phase 2a study results indicate a substantial treatment effect, especially in patients without Alzheimer's co-pathology. The findings are published in major peer-reviewed journals, reinforcing the potential of neflamapimod in treating these neurodegenerative diseases.
Read more →CRVO▲ +6.7%on this news· ran to +21% by day 3
CervoMed Announces Oral Presentation at CTAD 2023 Highlighting Phase 2b Neflamapimod Program for the Treatment of Patients with Dementia with Lewy Bodies CervoMed Inc. (NASDAQ: CRVO), a clinical-stage company focused on developing treatments for degenerative diseases of the brain, today announced it...
CervoMed Inc. announced an oral presentation at the CTAD 2023 conference, focusing on its Phase 2b study of neflamapimod for dementia with Lewy bodies. The study aims to confirm earlier efficacy results and is expected to complete enrollment in the first half of 2024. The presentation will discuss the study's design and its potential to provide a disease-modifying treatment.
Read more →CRVOCervoMed to Present at the 2023 Roth Healthcare Opportunities Conference CervoMed Inc. (NASDAQ: CRVO), a clinical-stage company focused on developing treatments for degenerative diseases of the brain, today announced it...
CervoMed Inc. will present at the 2023 Roth Healthcare Opportunities Conference on October 12, 2023. The company focuses on developing treatments for degenerative brain diseases, particularly with its investigational drug neflamapimod, which is in a Phase 2b study for dementia with Lewy bodies. The management team will also host one-on-one meetings during the event.
Read more →CRVO▼ -9.2%on this news
CervoMed Announces Publication in Neurology Results Showing a Blood Test at Study Entry Identified Patients Who Demonstrated Substantial Response to Neflamapimod in Dementia with Lewy Bodies
CervoMed Announces Publication in Neurology Results Showing a Blood Test at Study Entry Identified Patients Who Demonstrated Substantial Response to Neflamapimod in Dementia with Lewy Bodies
Read more →CRVO▼ -9.2%on this news
CervoMed Announces Publication in Neurology® Results Showing a Blood Test at Study Entry Identified Patients Who Demonstrated Substantial Response to Neflamapimod in Dementia with Lewy Bodies CervoMed Inc., a clinical stage company focused on developing treatments for degenerative diseases of the brain, today announced the publication...
CervoMed has published new analyses from its AscenD-LB Phase 2a trial in 'Neurology', revealing that patients with normal plasma ptau181 levels respond better to neflamapimod treatment for dementia with Lewy bodies. The findings suggest that excluding patients with elevated ptau181 in ongoing trials could enhance success rates. Neflamapimod is positioned as a potential disease-modifying treatment.
Read more →CRVO▼ -14%on this newsshared move
CervoMed to Present at H.C. Wainwright 25th Annual Global Investment Conference CervoMed Inc. (NASDAQ: CRVO), a clinical-stage company focused on developing treatments for degenerative diseases of the brain, today announced that...
CervoMed Inc. will present at the H.C. Wainwright 25th Annual Global Investment Conference on September 11. The company focuses on developing neflamapimod, an investigational treatment for degenerative brain diseases. CervoMed, formed from a merger in August 2023, is currently conducting a Phase 2b study for dementia with Lewy bodies.
Read more →CRVOCervoMed Announces Completion of Merger with EIP Pharma CervoMed Inc. (formerly known as Diffusion Pharmaceuticals Inc.) (NASDAQ: CRVO), now a clinical-stage company focused on developing treatments for...
CervoMed Inc., formerly Diffusion Pharmaceuticals, has completed its merger with EIP Pharma and will trade under the ticker CRVO starting August 17, 2023. The company focuses on developing neflamapimod, an oral stress kinase inhibitor for dementia with Lewy bodies. With a cash runway through Phase 2b clinical data expected in late 2024, CervoMed aims to be a leader in CNS therapeutics.
Read more →CRVODiffusion Pharmaceuticals Stockholders Approve Merger with EIP Pharma
Diffusion Pharmaceuticals Stockholders Approve Merger with EIP Pharma
Read more →CRVOEIP Pharma Announces First Patient Dosed in RewinD-LB Phase 2b Clinical Trial Evaluating Neflamapimod in Dementia with Lewy Bodies
EIP Pharma Announces First Patient Dosed in RewinD-LB Phase 2b Clinical Trial Evaluating Neflamapimod in Dementia with Lewy Bodies
Read more →CRVOEIP Pharma Announces First Patient Dosed in RewinD-LB Phase 2b Clinical Trial Evaluating Neflamapimod in Dementia with Lewy Bodies EIP Pharma Inc. ("EIP Pharma" or the "Company"), a privately held clinical-stage company focused on developing treatments for neurodegenerative...
EIP Pharma has initiated the RewinD-LB Phase 2b clinical trial, dosing its first patient with neflamapimod for dementia with Lewy bodies (DLB). This trial aims to confirm earlier positive results from Phase 2a, where neflamapimod improved cognition and function. The study is significant as DLB currently lacks approved treatments, and successful results could lead to the first approved therapy for this condition.
Read more →CRVOEIP Pharma to Present at Canaccord Genuity 43rd Annual Growth Conference
EIP Pharma to Present at Canaccord Genuity 43rd Annual Growth Conference
Read more →CRVOEIP Pharma to Present at Canaccord Genuity 43rd Annual Growth Conference EIP Pharma Inc., a clinical stage company focused on developing treatments for neurodegenerative diseases, today announced that the Company's senior...
EIP Pharma Inc. announced its participation in the Canaccord Genuity 43rd Annual Growth Conference, scheduled for August 9, 2023. The company's senior management will present and hold one-on-one meetings at the event. EIP Pharma is focused on developing neflamapimod, a treatment for neurodegenerative diseases, particularly dementia with Lewy bodies.
Read more →CRVOEIP Pharma Announces Presentation of Neuroimaging Data Exhibiting Potential Effects of Neflamapimod on Cholinergic Structure and Function at AD/PD 2023
EIP Pharma Announces Presentation of Neuroimaging Data Exhibiting Potential Effects of Neflamapimod on Cholinergic Structure and Function at AD/PD 2023
Read more →CRVOEIP Pharma and Diffusion Pharmaceuticals Announce Merger Agreement to Create Leading CNS-focused Company Treating Neurodegenerative Diseases
EIP Pharma and Diffusion Pharmaceuticals Announce Merger Agreement to Create Leading CNS-focused Company Treating Neurodegenerative Diseases
Read more →CRVONational Institute on Aging (NIA) awards $21M grant to support key phase 2b study of EIP Pharma's neflamapimod in dementia with Lewy bodies
National Institute on Aging (NIA) awards $21M grant to support key phase 2b study of EIP Pharma's neflamapimod in dementia with Lewy bodies
Read more →CRVOPresentation of MRI data at Clinical Trials and Alzheimer's Disease (CTAD) conference demonstrates potential of neflamapimod to positively impact the cholinergic degenerative process in early Alzheimer's disease (AD)
Presentation of MRI data at Clinical Trials and Alzheimer's Disease (CTAD) conference demonstrates potential of neflamapimod to positively impact the cholinergic degenerative process in early Alzheimer's disease (AD)
Read more →CRVOEIP Pharma Publishes Translational Data of Preclinical and Phase 2a Results for Neflamapimod in Dementia with Lewy Bodies: Nature Communications
EIP Pharma Publishes Translational Data of Preclinical and Phase 2a Results for Neflamapimod in Dementia with Lewy Bodies: Nature Communications
Read more →CRVOPresentation at 14th CTAD Conference November 10, 2021
Presentation at 14th CTAD Conference November 10, 2021
Read more →CRVOEIP Pharma Announces New Data Presentations from Phase 2 Treatment Trial in Dementia with Lewy Bodies at Upcoming Scientific Conference and New Board Appointment
EIP Pharma Announces New Data Presentations from Phase 2 Treatment Trial in Dementia with Lewy Bodies at Upcoming Scientific Conference and New Board Appointment
Read more →CRVOEIP Pharma appoints Dr. Marwan Sabbagh to Board of Directors
EIP Pharma appoints Dr. Marwan Sabbagh to Board of Directors
Read more →CRVOEIP Pharma Announces Publication of Preclinical Results Demonstrating Potential of Neflamapimod to Promote Functional Recovery after Ischemic Stroke
EIP Pharma Announces Publication of Preclinical Results Demonstrating Potential of Neflamapimod to Promote Functional Recovery after Ischemic Stroke
Read more →CRVOEIP Pharma Announces Presentation of Positive Clinical Trial Results with Neflamapimod at the 13th Clinical Trials in Alzheimer's Disease (CTAD) Meeting
EIP Pharma Announces Presentation of Positive Clinical Trial Results with Neflamapimod at the 13th Clinical Trials in Alzheimer's Disease (CTAD) Meeting
Read more →CRVOEIP Pharma Announces Positive Phase 2 Results for Neflamapimod in Mild-to-Moderate Dementia with Lewy bodies (DLB)
EIP Pharma Announces Positive Phase 2 Results for Neflamapimod in Mild-to-Moderate Dementia with Lewy bodies (DLB)
Read more →CRVOEIP Pharma Announces Presentation of Phase 2b Clinical Trial Results of Neflamapimod in Early-stage Alzheimer's Disease at Clinical Trials in Alzheimer's Disease (CTAD) meeting
EIP Pharma Announces Presentation of Phase 2b Clinical Trial Results of Neflamapimod in Early-stage Alzheimer's Disease at Clinical Trials in Alzheimer's Disease (CTAD) meeting
Read more →CRVOEIP Pharma Announces U.S. FDA Grants Fast-Track Designation to Neflamapimod as a Treatment for Dementia with Lewy Bodies (DLB)
EIP Pharma Announces U.S. FDA Grants Fast-Track Designation to Neflamapimod as a Treatment for Dementia with Lewy Bodies (DLB)
Read more →CRVOEIP Pharma Announces Clinical Trial Results of REVERSE-SD, a Phase 2b Study of Neflamapimod in Early-stage Alzheimer's Disease
EIP Pharma Announces Clinical Trial Results of REVERSE-SD, a Phase 2b Study of Neflamapimod in Early-stage Alzheimer's Disease
Read more →CRVOEIP Pharma to Present at Canaccord Genuity 39th Annual Growth Conference
EIP Pharma to Present at Canaccord Genuity 39th Annual Growth Conference
Read more →CRVOEIP Pharma Announces Presentation of Preclinical Data Demonstrating Effects of p38a Kinase Inhibitor Neflamapimod on the Neurodegenerative Process
EIP Pharma Announces Presentation of Preclinical Data Demonstrating Effects of p38a Kinase Inhibitor Neflamapimod on the Neurodegenerative Process
Read more →CRVOEIP Pharma Initiates New Study with Neflamapimod for the Treatment of Cognitive Deficits in Patients with Dementia with Lewy Bodies
EIP Pharma Initiates New Study with Neflamapimod for the Treatment of Cognitive Deficits in Patients with Dementia with Lewy Bodies
Read more →CRVOEIP Pharma Appoints Noel Donnelly as CFO
EIP Pharma Appoints Noel Donnelly as CFO
Read more →CRVOEIP Pharma to Host KOL Breakfast Briefing on Potential of Neflamapimod in Alzheimer's Disease and Dementia with Lewy Bodies
EIP Pharma to Host KOL Breakfast Briefing on Potential of Neflamapimod in Alzheimer's Disease and Dementia with Lewy Bodies
Read more →CRVOEIP Pharma to Present at Upcoming Investor Conferences in June
EIP Pharma to Present at Upcoming Investor Conferences in June
Read more →CRVOEIP Pharma Closes $11.2 Million Financing Round to Advance Development of Neflamapimod in Additional Neurodegenerative Disease Indications
EIP Pharma Closes $11.2 Million Financing Round to Advance Development of Neflamapimod in Additional Neurodegenerative Disease Indications
Read more →CRVOEIP Pharma to Present at BIO CEO Investor Conference
EIP Pharma to Present at BIO CEO Investor Conference
Read more →CRVOEIP Pharma Announces Phase 2B REVERSE-SD Study of Neflamapimod Fully Enrolled
EIP Pharma Announces Phase 2B REVERSE-SD Study of Neflamapimod Fully Enrolled
Read more →CRVOEIP Pharma Announces Clinical Study Presentations at the 11th Clinical Trials on Alzheimer's Disease Conference and Provides Update on Phase 2b Clinical Study Enrollment
EIP Pharma Announces Clinical Study Presentations at the 11th Clinical Trials on Alzheimer's Disease Conference and Provides Update on Phase 2b Clinical Study Enrollment
Read more →CRVOEIP Pharma Secures $20.5 Million in Series B Financing
EIP Pharma Secures $20.5 Million in Series B Financing
Read more →CRVOEIP Pharma Announces Publication of Positive Alzheimer's Disease Clinical Study Data with Neflamapimod
EIP Pharma Announces Publication of Positive Alzheimer's Disease Clinical Study Data with Neflamapimod
Read more →CRVODiffusion Pharmaceuticals Reports Second Quarter 2017 Financial Results and Provides Business Update CHARLOTTESVILLE, Va. (
Diffusion Pharmaceuticals Reports Second Quarter 2017 Financial Results and Provides Business Update CHARLOTTESVILLE, Va. (August 14, 2017) - Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) ("Diffusion" or "the Company"), a clinical-stage biotechnology company focused on the devel
Read more →CRVOEIP Pharma announces presentation of new mechanism of action data regarding neflamapimod (VX-745) at Alzheimer's Association International Conference (AAIC)
EIP Pharma announces presentation of new mechanism of action data regarding neflamapimod (VX-745) at Alzheimer's Association International Conference (AAIC)
Read more →CRVOEIP Pharma announces presentation of new positive clinical data with neflamapimod (VX-745) at Alzheimer's Association International Conference (AAIC)
EIP Pharma announces presentation of new positive clinical data with neflamapimod (VX-745) at Alzheimer's Association International Conference (AAIC)
Read more →CRVONASDAQ: DFFN Diffusion Pharmaceuticals Provides Corporate Highlights and Reports Financial First Quarter 2017 Results Charlottesville, Virginia (
Diffusion Pharmaceuticals Provides Corporate Highlights and Reports Financial First Quarter 2017 Results Charlottesville, Virginia (May 15, 2017) - Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN), a clinical stage biotechnology company focused on the development of novel small mol
Read more →CRVONASDAQ: DFFN Diffusion Pharmaceuticals Announces Closing of Oversubscribed Private Placement Raises Aggregate Gross Proceeds of $25.0 million Charlottesville, Virginia (
Diffusion Pharmaceuticals Announces Closing of Oversubscribed Private Placement Raises Aggregate Gross Proceeds of $25.0 million Charlottesville, Virginia (April 3, 2017) - Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN), a clinical stage biotechnology company focused on the deve
Read more →CRVODiffusion Pharmaceuticals Provides Corporate Highlights and Reports 2016 Financial Results Charlottesville, Virginia (
Diffusion Pharmaceuticals Provides Corporate Highlights and Reports 2016 Financial Results Charlottesville, Virginia (March 31, 2017) - Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN), a clinical stage biotechnology company focused on the development of novel small molecule thera
Read more →CRVONASDAQ: DFFN Diffusion Pharmaceuticals Provides Corporate Highlights and Reports Financial Third Quarter 2016 Results Charlottesville, Virginia ( November 14 , 2016) - Diffusion Pharmaceuticals Inc.
Diffusion Pharmaceuticals Provides Corporate Highlights and Reports Financial Third Quarter 2016 Results Charlottesville, Virginia (November 14, 2016) - Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN), a clinical stage biotechnology company focused on the development of novel sma
Read more →CRVOOTCQX: DFFN Diffusion Pharmaceuticals Announc es Uplisting to NASDAQ Capital Market Charlottesville, Virginia ( November 8 , 2016) - Diffusion Pharmaceuticals Inc. (OTCQX: DFFN), a clinical stage bi
Diffusion Pharmaceuticals Announces Uplisting to NASDAQ Capital Market Charlottesville, Virginia (November 8, 2016) - Diffusion Pharmaceuticals Inc. (OTCQX: DFFN), a clinical stage biotechnology company focused on the development of novel small molecule therapeutics for cancer a
Read more →CRVOEIP Pharma announces positive results with neflamapimod (VX-745) in two Phase 2a clinical trials in patients with Early Alzheimer's Disease
EIP Pharma announces positive results with neflamapimod (VX-745) in two Phase 2a clinical trials in patients with Early Alzheimer's Disease
Read more →CRVOEIP Pharma announces issuance of multiple new patents covering VX-745, a selective p38 MAP kinase alpha inhibitor for Alzheimer's disease and ischemic stroke recovery
EIP Pharma announces issuance of multiple new patents covering VX-745, a selective p38 MAP kinase alpha inhibitor for Alzheimer's disease and ischemic stroke recovery
Read more →CRVOOTCQX: DFFN Diffusion Pharmaceuticals Provides Corporate Highlights and Reports Financial Second Quarter 2016 Results Charlottesville, Virginia (August 15 , 2016) - Diffusion Pharmaceuticals Inc. (O
Diffusion Pharmaceuticals Provides Corporate Highlights and Reports Financial Second Quarter 2016 Results Charlottesville, Virginia (August 15, 2016) - Diffusion Pharmaceuticals Inc. (OTCQX: DFFN), a clinical stage biotechnology company focused on the development of novel small
Read more →CRVOOTCQX: DFFN Diffusion Pharmaceuticals Provides Corporate Highlights and Reports First Quarter 2016 Results Charlottesville, Virginia (May 16 , 2016) - Diffusion Pharmaceuticals Inc. (OTCQX: DFFN), a
Diffusion Pharmaceuticals Provides Corporate Highlights and Reports First Quarter 2016 Results Charlottesville, Virginia (May 16, 2016) - Diffusion Pharmaceuticals Inc. (OTCQX: DFFN), a clinical stage biotechnology company focused on the development of novel small molecule thera
Read more →CRVOOTCQX: DFFN Diffusion Pharmaceuticals Appoints Thomas Byrne as General Counsel Charlottesville, Virginia (
Diffusion Pharmaceuticals Appoints Thomas Byrne as General Counsel Charlottesville, Virginia (April 1, 2016) - Diffusion Pharmaceuticals Inc. (OTCQX: DFFN), a clinical stage biotechnology company focused on the development of novel small molecule therapeutics for cancer, today a
Read more →CRVOOTCQX: DFFN Diffusion Pharmaceuticals Announce s Stock Ticker Symbol Change to DFFN Charlottesville, Virginia (
Diffusion Pharmaceuticals Announces Stock Ticker Symbol Change to DFFN Charlottesville, Virginia (January 25, 2016) -Diffusion Pharmaceuticals Inc., a clinical stage biotechnology company focused on the development of novel small molecule therapeutics for cancer, today announced
Read more →CRVODiffusion P harmaceuticals Completes Merger with RestorGenex and Becomes a Publicly Traded Oncology-Focused Biotechnology Company Charlottesville, VA
Diffusion Pharmaceuticals Completes Merger with RestorGenex and Becomes a Publicly Traded Oncology-Focused Biotechnology Company Charlottesville, VA, January 8, 2016 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals LLC, a clinical-stage biotechnology company focused on the developm
Read more →CRVOEIP Pharma announces scientific publication of results demonstrating pro-cognitive effects in aged rats of VX-745, a clinical stage selective p38 MAP kinase alpha Inhibitor
EIP Pharma announces scientific publication of results demonstrating pro-cognitive effects in aged rats of VX-745, a clinical stage selective p38 MAP kinase alpha Inhibitor
Read more →CRVOOTCQX: RESX RestorGenex and Diffusion Pharmaceuticals Announce Merger Agreement --Proposed Merger Would Create an Oncology-focused Bio technology Company -- --Combined Company Expects to Initiate Ph
RestorGenex and Diffusion Pharmaceuticals Announce Merger Agreement --Proposed Merger Would Create an Oncology-focused Biotechnology Company -- --Combined Company Expects to Initiate Phase III Clinical Trial in GBM for Orphan Drug-designated TSC in 2016-- Buffalo Grove, Illino
Read more →CRVOOTCQX: RESX RestorGenex Reports Third Quarter 2015 Financial Results Buffalo Grove , Illinois ( November 1 2 , 201 5 ) - RestorGenex Corporation (OTCQX: RESX), a specialty biopharmaceutical company
Third Quarter 2015 Financial Results Buffalo Grove, Illinois (November 12, 2015) - RestorGenex Corporation (OTCQX: RESX), a specialty biopharmaceutical company focused on developing products for oncology, ophthalmology and dermatology, today reported on its cash balance and fina
Read more →CRVOOTCQX: RESX RestorGenex Reports Financial Results Buffalo Grove, Illinois (
RestorGenex Reports Financial Results Buffalo Grove, Illinois (August 12, 2015) - RestorGenex Corporation (OTCQX: RESX), a specialty biopharmaceutical company focused on developing products for oncology, ophthalmology and dermatology, today reported its cash balance and financia
Read more →CRVOEIP Pharma announces first patient dosing in phase 2 clinical studies of a novel brain-targeted anti-inflammatory drug candidate, VX-745, for the treatment of Alzheimer's disease (AD)
EIP Pharma announces first patient dosing in phase 2 clinical studies of a novel brain-targeted anti-inflammatory drug candidate, VX-745, for the treatment of Alzheimer's disease (AD)
Read more →CRVOOTCQB: RESX RestorGenex Reports First Quarter 2015 Financial Results Buffalo Grove, Illinois (
RestorGenex Reports First Quarter 2015 Financial Results Buffalo Grove, Illinois (May 11, 2015) - RestorGenex Corporation (OTCQB: RESX), a specialty biopharmaceutical company focused on developing products for oncology, ophthalmology and dermatology, today reported its financial
Read more →CRVOOTCQB: RESX RestorGenex Reports Corporate Highlights and Financial Results for 2014 Buffalo Grove, Illinois (
Corporate Highlights and Financial Results for 2014 Buffalo Grove, Illinois (April 6, 2015) - RestorGenex Corporation (OTCQB: RESX), a specialty biopharmaceutical company focused on developing products for oncology, ophthalmology and dermatology, reported on its cash balance as
Read more →CRVOLOGO] This presentation includes forward-looking statements under the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts contained in this presentation, including s
Peak effect observed between Days 7-10 and remained through Day 21 Unlike Flutamide at these doses, no decreases of the untreated flank organ were observed. At necropsy, no evidence of antiandrogenic effects on internal androgen-sensitive tissues Mean (SE) Flank Organ Area Differ
Read more →CRVOOTCQB: RESX RestorGenex Reports Third Quarter 2014 Financial Results Buffalo Grove, Illinois (
Third Quarter 2014 Financial Results Buffalo Grove, Illinois (November 12, 2014) - RestorGenex Corporation (OTCQB: RESX), a specialty biopharmaceutical company initially focused on developing products for dermatology, ophthalmology and women s health, today reported on its cash
Read more →CRVOOTCQB: RESX RestorGenex Reports Second Quarter 2014 Financial Results CHICAGO, Illinois (
Second Quarter 2014 Financial Results CHICAGO, Illinois (August 14, 2014) - RestorGenex Corporation (OTCQB: RESX), a specialty biopharmaceutical company initially focused on developing products for dermatology, ophthalmology and women s health, today reported on its cash balance
Read more →CRVOOTC QB: RESX RestorGenex Announces Management Changes CHICAGO, Illinois (
RestorGenex Announces Illinois (July 8, 2014) - RestorGenex Corporation (OTCQB: RESX), a specialty biopharmaceutical company initially focused on developing products for dermatology, ophthalmology and women's health, announced today several management changes. RestorGenex has
Read more →CRVORestorGenex Completes Acquisition of Two Biopharmaceutical Companies LOS ANGELES , California (
RestorGenex Completes Acquisition of Two Biopharmaceutical Companies LOS ANGELES, California (March 31, 2014)-RestorGenex Corporation (OTCQB:SMDID), announced today the closing of its acquisition of two biopharmaceuticals companies, Paloma Pharmaceuticals, Inc. and VasculoMed
Read more →CRVORestorGenex Names Stephen M. Simes as Chief Executive Officer Chicago, Illinois (
RestorGenex Names Stephen M. Simes as Chief Executive Officer Chicago, Illinois (March 10, 2014) - RestorGenex (OTCBB: SMDID) announced today that it has named Stephen M. Simes as its Chief Executive Officer, to lead the company. Mr. Simes formerly served as vice chairman, pr
Read more →CRVOStratus Media Group Acquires Paloma Pharmaceuticals, Inc. and VasculoMedics, Inc.
Stratus Media Group Acquires Paloma Pharmaceuticals, Inc. and VasculoMedics, Inc. LOS ANGELES--Stratus Media Group, Inc., (OTCBB: SMDI) announced today the acquisition, through merger, of two biotechnology companies, Paloma Pharmaceuticals, Inc. and VasculoMedics, Inc. With t
Read more →CRVOHYGEIA THERAPEUTICS, INC. AND CANTERBURY LABORATORIES, llc
THERAPEUTICS, INC. AND CANTERBURY LABORATORIES, llc COMBINED FINANCIAL STATEMENTS THERAPEUTICS, INC. AND CANTERBURY LABORATORIES, llc FINANCIAL STATEMENTS FINANCIAL STATEMENTS Report of Independent Registered Public Accounting Firm 3 Balance Sheets 4 Statements of Operati
Read more →CRVOStratus Media Group Enters Dermatological and Restorative Medicine Industry, Signs Merger Agreement with Two Biopharmaceutical Companies, Changes Corporate Name to Restorgenex, and Announces New Chairman and Vice Chairma
Stratus Media Group Enters Dermatological and Restorative Medicine Industry, Signs Merger Agreement with Two Biopharmaceutical Companies, Changes Corporate Name to Restorgenex, and Announces New Chairman and Vice Chairman September 29, 2013 09:00 PM Pacific Daylight Time LOS
Read more →CRVOJACK SCHNEIDER NAMED TO BOARD ROLE AT STRATUS MEDIA GROUP, INC. Veteran Allen & Company Executive To Advise Global Events Company LOS ANGELES, CA (
JACK SCHNEIDER NAMED TO BOARD ROLE AT STRATUS MEDIA GROUP, INC. Veteran Allen & Company Executive To Advise Global Events Company LOS ANGELES, CA (December 1, 2011) -- Stratus Media Group, Inc. (OTCBB:SMDI), a global live events company, announced today the appointment of Jack
Read more →CRVOStratus Media Group Secures Ninety Five Percent Ownership of ProElite, Inc. Stratus Media Group to Relaunch ProElite Events in 2011 Third Quarter SANTA BARBARA, Calif.--(BUSINESS WIRE)
Stratus Media Group Secures Ninety Five Percent Ownership of ProElite, Inc. Stratus Media Group to Relaunch ProElite Events in 2011 Third Quarter SANTA BARBARA, Calif.--(BUSINESS WIRE)--June 15, 2011--Stratus Media Group, Inc. (OTCBB:SMDI), a live entertainment company, announc
Read more →CRVOSTRATUS MEDIA GROUP CLOSES $14.1 MILLION FINANCING FUNDING AND CORPORATE REALIGNMENT WILL FACILITATE NEAR-TERM GROWTH New York City, NY
STRATUS MEDIA GROUP CLOSES $14.1 MILLION FINANCING FUNDING AND CORPORATE REALIGNMENT WILL FACILITATE NEAR-TERM GROWTH New York City, NY-- May 26, 2011 -- Stratus Media Group, Inc. (OTCBB:SMDI), a global owner, operator of live entertainment events and owner of the Stratus Rewar
Read more →CRVOProElite Relaunch under Management of Stratus Media Group International MMA Events Planned for 2010 SANTA BARBARA, Calif.--(BUSINESS WIRE)
Relaunch under Management of Stratus Media Group MMA Events Planned for 2010 SANTA BARBARA, Calif.--(BUSINESS WIRE)--February 23, 2010--Stratus Media Group, Inc. (OTCBB:SMDI), a live entertainment company, announced today that Stratus has assumed control over the board of dir
Read more →CRVOUnassociated Document NEWS RELEASE CONTACT: Gary S. Maier Maier & Company, Inc. (310) 442-9852 STRATUS MEDIA GROUP SIGNS AGREEMENT TO PURCHASE SWISS AUTO RACING ORGANIZATION -- Transaction Provides European Base to Expan
MEDIA GROUP SIGNS AGREEMENT TO PURCHASE AUTO RACING ORGANIZATION Transaction Provides European Base to Expand Entertainment and Marketing-Related ANGELES, CA - July 30, 2008 - Stratus Media Group, Inc. (OTC:SMDI.PK) today announced it has signed a definitive purchase agreemen
Read more →CRVOGary S. Maier Maier & Company, Inc. (310) 442-9852 FERIS INTERNATIONAL ADOPTS NEW CORPORATE NAME -- New Trading Symbol Issued
INTERNATIONAL ADOPTS NEW CORPORATE NAME New Trading Symbol Issued -- ANGELES, CA - July 14, 2008 - Feris International, Inc. (OTC: SMDI.PK), which completed a reverse merger and exchanger in March with Pro Sports & Entertainment, today announced the adoption of Stratus Media
Read more →CRVOGary S. Maier Maier & Company, Inc. (310) 442-9852
NEWS RELEASE CONTACT: Gary S. Maier Maier & Company, Inc. (310) 442-9852 INTERNATIONAL SIGNS AGREEMENT TO PURCHASE TALENT AND MODELING ANGELES, CA - April 23, 2008 - Feris International (OTC: FSIT.PK) today announced it has signed a definitive purchase agreement to acquire N
Read more →Competitive Position
How CRVO ranks across every disease it competes inCompetitive Position is a premium feature
See how CRVO ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial